Post by Telix Pharmaceuticals Limited

What are the key challenges in brain tumor management today, and how could theranostics shape the future of diagnosis and treatment? Telix’s upcoming educational webinar will explore these questions and more, with physician perspectives on emerging therapeutic directions and case studies from Telix’s IPAX series of trials and early access program with TLX101-Tx (¹³¹I-iodofalan). The discussion will also evaluate the role of precision diagnostics, including with Telix’s glioma imaging candidate TLX101-Px (Pixclara®, floretyrosine F 18). Presentations will be followed by Q&A. Register here: https://lnkd.in/gg27dfX2 TLX101-Tx and TLX101-Px have not received a marketing authorization in any jurisdiction. Pixclara brand name subject to final regulatory approval.

Video Content